Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is currently priced at $9.85, with a 24-hour trading volume of 239.90K. It has seen a +9.57% increased in the last 24 hours and a +4.90% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.39 pivot point. If it approaches the $9.92 resistance level, significant changes may occur.

Annovis Bio Inc Stock (ANVS) Financials Data

Annovis Bio Inc (ANVS) Net Income 2024

ANVS net income (TTM) was -$41.72 million for the quarter ending September 30, 2023, a -77.39% decrease year-over-year.

Annovis Bio Inc (ANVS) Cash Flow 2024

ANVS recorded a free cash flow (TTM) of -$34.21 million for the quarter ending September 30, 2023, a -121.11% decrease year-over-year.

Annovis Bio Inc (ANVS) Earnings per Share 2024

ANVS earnings per share (TTM) was -$4.83 for the quarter ending September 30, 2023, a -65.98% decline year-over-year.

Annovis Bio Inc Stock (ANVS) Latest News

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.